• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

The mechanisms of sudden-onset type adverse reactions to oseltamivir

tetano

Editor, Senior Moderator
Acta Neurol Scand. 2016 Jun 30. doi: 10.1111/ane.12629. [Epub ahead of print]
[h=1]The mechanisms of sudden-onset type adverse reactions to oseltamivir.[/h] Hama R[SUP]1[/SUP], Bennett CL[SUP]2[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] Oseltamivir is contraindicated for people aged 10-19 in principle in Japan, due to concern about abnormal behaviours. Sudden death is another concern. This review examines growing evidence of their association and discusses underlying mechanisms of these sudden-onset type reactions to oseltamivir. First, the importance of animal models and the concept of human equivalent dose (HED) is summarized. Second, the specific condition for oseltamivir use, influenza infection, is reviewed. Third, findings from toxicity studies conducted prior to and after the marketing of oseltamivir are reported on to provide context on the observation of a possible causal association. Fourth, similarity and consistency of toxicity in humans with that in other animals is described. Finally, coherence of toxicokinetic and molecular level of evidence (channels, receptors and enzymes), including differences from the toxicity of other neuraminidase inhibitors, is reviewed. It is concluded that unchanged oseltamivir has various effects on the central nervous system (CNS) that may be related to clinical findings including hypothermia, abnormal behaviours including with fatal outcome, and sudden death. Among receptors and enzymes related to CNS action, it is known that oseltamivir inhibits nicotinic acetylcholine receptors, which are closely related to hypothermia, as well as human monoamine oxidase-A (MAO-A), which is closely related to abnormal or excitatory behaviours. Receptors such as GABA[SUB]A[/SUB] , GABA[SUB]B[/SUB] and NMDA and their related receptors/channels including Na[SUP]+[/SUP] and Ca[SUP]2+[/SUP] channels are thought to be other candidates for investigation related to respiratory suppression followed by sudden death and psychotic reactions (both acute and chronic), respectively.
? 2016 The Authors. Acta Neurologica Scandinavica Published by John Wiley & Sons Ltd.


[h=4]KEYWORDS:[/h] abnormal behaviour; monoamine oxidase-A; neuropsychiatric adverse effects; nicotinic acetylcholine receptor; oseltamivir; respiratory arrest; sudden death

PMID: 27364959 DOI: 10.1111/ane.12629
[PubMed - as supplied by publisher]
 
Back
Top Bottom